---
document_datetime: 2023-09-21 17:59:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/prandin-epar-procedural-steps-taken-authorisation_en.pdf
document_name: prandin-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3795832
conversion_datetime: 2025-12-21 22:36:42.844089
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant Novo  Nordisk  A/S  submitted on 2 June 2000  an application for Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Prandin,  through  the  centralised procedure.

This submission concerns an abridged application for three strengths of Prandin tablets 0.5 mg, 1 mg and  2  mg.  This  application  has  been  in  accordance  with  Chapter  II,  Article  4.8.a.  (i)  of  Council Directive  65/65/EEC  of  26  January  1995,  as  amended.  The  Marketing  Authorisation  Holder  of NovoNorm tablets, Novo Nordisk A/S, Denmark, consented to the pharmacological, toxicological and clinial data contained in the original file of NoveNorm to be used in the purpose of this application.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur:

Dr S. Bronswijk

## Licensing status:

This  product was not licensed in the  European Union  at the time  of  submission  of  the  application. However,  an  essentially  similar  product,  under  the  name  of  NovoNorm,  was  authorised  in  the  EU through the centralised procedure on 17 August 1998.

## 2. Steps taken for the assessment of the product

- The procedure started on 20 June 2000.
- The  Rapporteur  and  Co-Rapporteur's  joint  assessment  report  was  circulated  to  all  CPMP Members on 14 August 2000.
- During  the  meeting  on  19-21  September  2000  the  CPMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee  issued  a  positive  Opinion  for granting a Marketing Authorisation to Prandin on 21 September 2000.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decision on 29 January 2001.

Co-Rapporteur:

Pharm J. Genoux-Hames